Table 1 Characteristics of included systematic reviews: total and IfR statement: yes/no
Total | IfR: Yes | IfR: No | |
|---|---|---|---|
N = 261 (%) | n = 210 (%) | n = 51 (%) | |
Patients: | |||
Lung cancer | 68 (26.1) | 53 (25.2) | 15 (29.4) |
Colorectal cancer | 45 (17.2) | 35 (16.7) | 10 (19.6) |
Breast cancer | 31 (11.9) | 26 (12.4) | 5 (9.8) |
Gastric cancer | 30 (11.5) | 24 (11.4) | 6 (11.8) |
Pancreatic cancer | 19 (7.3) | 16 (7.6) | 3 (5.9) |
Mixed types of cancer | 17 (6.5) | 12 (5.7) | 5 (9.8) |
Genitourinary cancer | 11 (4.2) | 9 (4.3) | 2 (3.9) |
Brain metastases | 10 (3.8) | 9 (4.3) | 1 (2.0) |
Esophageal cancer | 9 (3.4) | 8 (3.8) | 1 (2.0) |
Hepatocellular carcinoma | 6 (2.3) | 5 (2.4) | 1 (2.0) |
Bone metastases | 3 (1.1) | 3 (1.4) | 0 (0.0) |
Other | 12 (4.6) | 10 (4.8) | 2 (3.9) |
Intervention: | |||
Pharmacological treatment | 244 (93.5) | 195 (92.9) | 49 (96.1) |
Radiotherapy | 10 (3.8) | 10 (4.8) | 0 (0.0) |
Surgery | 7 (2.7) | 5 (2.4) | 2 (3.9) |
Control: | |||
Standard care | 156 (59.8) | 131 (62.4) | 25 (49.0) |
Standard care and active comparator | 57 (21.8) | 42 (20.0) | 15 (29.4) |
Standard care and placebo | 41 (15.7) | 31 (14.8) | 10 (19.6) |
Same intervention but modified (e.g. different doses) | 7 (2.7) | 6 (2.9) | 1 (2.0) |
Primary outcome of review: | |||
Not defined | 126 (48.3) | 95 (45.2) | 31 (60.8) |
Overall survival | 84 (32.2) | 70 (33.3) | 14 (27.5) |
Progression-free survival | 21 (8.0) | 19 (9.0) | 2 (3.9) |
Complete response | 12 (4.6) | 10 (4.8) | 2 (3.9) |
Disease event | 5 (1.9) | 4 (1.9) | 1 (2.0) |
Other | 13 (5.0) | 12 (5.7) | 1 (2.0) |
Use of GRADE: | |||
No | 231 (88.5) | 183 (87.1) | 48 (94.1) |
Yes | 30 (11.5) | 27 (12.9) | 3 (5.9) |
Addressing clinical relevance of results: | |||
No | 151 (57.9) | 113 (53.8) | 38 (74.5) |
Yes | 110 (42.1) | 97 (46.2) | 13 (25.5) |
Type of review: | |||
Neither using PRISMA nor a Cochrane Review | 129 (49.4) | 100 (47.6) | 29 (56.9) |
Review using PRISMA | 103 (39.5) | 81 (38.6) | 22 (43.1) |
Cochrane Review | 29 (11.1) | 29 (13.8) | 0 (0.0) |
Registration of review: | |||
No | 222 (85.1) | 174 (82.9) | 48 (94.1) |
Yes | 39 (14.9) | 36 (17.1) | 3 (5.9) |
AMSTAR 2 overall rating: | |||
critically low | 230 (88.1) | 180 (85.7) | 50 (98.0) |
high | 12 (4.6) | 12 (5.7) | 0 (0.0) |
low | 11 (4.2) | 10 (4.8) | 1 (2.0) |
moderate | 8 (3.1) | 8 (3.8) | 0 (0.0) |